Letter to the Editor: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease-October 2024 updates to AASLD practice guidance
Hepatology
.
2025 Jun 1;81(6):E158-E159.
doi: 10.1097/HEP.0000000000001264.
Epub 2025 Feb 17.
Authors
Averell H Sherker
1
,
Jay H Hoofnagle
Affiliation
1
Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
PMID:
39960317
DOI:
10.1097/HEP.0000000000001264
No abstract available